Australian company Atomo Diagnostics (ASX:AT1) has expanded its existing COVID-19 rapid test partnership with Access Bio.
Under the expanded partnership, Atomo will have non-exclusive rights to market and distribute Access’ COVID-19 rapid antigen test in Australia, New Zealand and India, branded the Atomo COVID-19 Antigen Test, subject to obtaining the required regulatory approvals in each jurisdiction.
The Atomo COVID-19 rapid antigen test is a nasopharyngeal swab test designed to screen for antigens produced in response to COVID-19 infections at the point of testing.
The company said unlike the general nasal swab testing in Australia, which typically uses molecular PCR assays to test for the presence of the virus and must go to a central laboratory for processing, its test is processed at the point of care and results are available after ten minutes.
It said the rapid antigen test has the potential to complement its existing TGA approved AtomoRapid COVID-19 rapid antibody test that identifies whether a patient has developed antibodies to the virus and is most accurate around 15 days from exposure.
According to Atomo’s co-founder and managing director, John Kelly
Mr. Kelly added